David Risinger
Stock Analyst at Leerink Partners
(3.59)
# 812
Out of 4,941 analysts
168
Total ratings
65.17%
Success rate
14.16%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $172.78 | -11.45% | 4 | May 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $387.77 | +29.72% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $556.56 | +49.85% | 8 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $198.64 | +3.71% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.55 | +56.82% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $21.86 | +215.65% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.80 | +175.86% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $13.95 | +215.41% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $30.00 | +410.00% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $11.92 | -16.11% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $2.06 | -2.91% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $20.09 | +133.95% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $284.98 | +11.59% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $17.15 | -35.86% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $639.43 | -28.37% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $64.04 | -34.42% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $120.02 | -24.18% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $24.65 | +94.73% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.58 | -13.61% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.05 | +308.84% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $113.33 | +55.30% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $10.12 | +58.10% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $23.07 | +95.06% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $7.00 | +400.00% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $17.43 | +135.23% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $149.77 | +16.18% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $35.86 | +42.22% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $16.60 | -51.81% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $80.30 | +10.83% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $9.02 | -66.74% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $27.43 | -41.67% | 9 | Apr 2, 2020 |
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $172.78
Upside: -11.45%
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $387.77
Upside: +29.72%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $556.56
Upside: +49.85%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $198.64
Upside: +3.71%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.55
Upside: +56.82%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $21.86
Upside: +215.65%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.80
Upside: +175.86%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $13.95
Upside: +215.41%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $30.00
Upside: +410.00%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $11.92
Upside: -16.11%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $2.06
Upside: -2.91%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $20.09
Upside: +133.95%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $284.98
Upside: +11.59%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $17.15
Upside: -35.86%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $639.43
Upside: -28.37%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $64.04
Upside: -34.42%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $120.02
Upside: -24.18%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $24.65
Upside: +94.73%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.58
Upside: -13.61%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.05
Upside: +308.84%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $113.33
Upside: +55.30%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $10.12
Upside: +58.10%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $23.07
Upside: +95.06%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $7.00
Upside: +400.00%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $17.43
Upside: +135.23%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $149.77
Upside: +16.18%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $35.86
Upside: +42.22%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $16.60
Upside: -51.81%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $80.30
Upside: +10.83%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $9.02
Upside: -66.74%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $27.43
Upside: -41.67%